21 CFR Part 212 · Current Good Manufacturing Practice for Positron Emission Tomography Drugs

§ 212.20 What activities must I perform to ensure drug quality?

Subpart C - Quality Assurance Official text on eCFR Amendment history

(a) Production operations. You must oversee production operations to ensure that each PET drug meets the requirements of the act as to safety and has the identity and strength, and meets the quality and purity characteristics, that it is supposed to have.

(b) Materials. You must examine and approve or reject components, containers, closures, in-process materials, packaging materials, labeling, and finished dosage forms to ensure compliance with procedures and specifications affecting the identity, strength, quality, or purity of a PET drug.

(c) Specifications and processes. You must approve or reject, before implementation, any initial specifications, methods, processes, or procedures, and any proposed changes to existing specifications, methods, processes, or procedures, to ensure that they maintain the identity, strength, quality, and purity of a PET drug. You must demonstrate that any change does not adversely affect the identity, strength, quality, or purity of any PET drug.

(d) Production records. You must review production records to determine whether errors have occurred. If errors have occurred, or a production batch or any component of the batch fails to meet any of its specifications, you must determine the need for an investigation, conduct investigations when necessary, and take appropriate corrective actions.

(e) Quality assurance. You must establish and follow written quality assurance procedures.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 212.20

Form FDA 483 observations citing this section, fiscal years 2012–2026 (Drugs).

  • Written QA procedures established, followed 52
  • Determination need for investigation 31
  • Oversight of production operations 6
  • Specifications and processes 5
  • Examine, approve or reject 4
  • Adverse effects of changes made 2

Warning letters citing § 212.20

3 FDA warning letters since 2017 cite this section :

Amendment history

Federal Register documents that created or amended this section.